p.130 抽出テキスト

21) Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesth Analg 1995;80:296‒302 22) Mucci‒LoRusso P, Berman BS, Silberstein PT, et al. Controlled‒release oxycodone compared with controlled‒release morphine in the treatment of cancer pain:a randomized, double‒ blind, parallel‒group study. Eur J Pain 1998;2:239‒49 23) Parris WC, Johnson BW Jr, Croghan MK, et al. The use of controlled‒release oxycodone for the treatment of chronic cancer pain:a randomized, double‒blind study. J Pain Symptom Manage 1998;16:205‒11 24) Salzman RT, Roberts MS, Wild J, et al. Can a controlled‒release oral dose form of oxycodone be used as readily as an immediate‒release form for the purpose of titrating to stable pain control? J Pain Symptom Manage 1999;18:271‒9 25) Stambaugh JE, Reder RF, Stambaugh MD, et al. Double‒blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled‒ and immediate‒release oral oxycodone in cancer pain patients. J Clin Pharmacol 2001;41:500‒6 26) 武田文和,舘野政也,小山靖夫,他.癌患者の疼痛治療におけるS‒8117(塩酸オキシコドン

徐放錠)と硫酸モルヒネ徐放錠との比較試験―第III相臨床試験.臨医薬2005;21:295‒313 III章推奨